NASDAQ: DCOYDecoy Therapeutics Inc Stock Ownership - Who owns Decoy Therapeutics?
Insider buying vs selling
Have Decoy Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Arnold C. Hanish | Director | 2025-12-30 | 15 | $0.64 | $9.60Sell |
| Arnold C. Hanish | Director | 2025-12-30 | 12 | $0.64 | $7.68Sell |
| Arnold C. Hanish | Director | 2025-11-20 | 5,000 | $0.75 | $3.74kBuy |
| Mark J. Rosenblum | Exec VP Finance CFO | 2025-11-20 | 20,000 | $0.80 | $16.00kBuy |
DCOY insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when DCOY insiders and whales buy or sell their stock.
DCOY Shareholders
What type of owners hold Decoy Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Christoph H. Westphal | 1,268.46% | 8,310,759 | $14.71M | Insider |
| Boston Foundation Inc | 335.78% | 2,200,000 | $3.89M | Insider |
| Roderick MacKinnon | 65.83% | 431,277 | $763.36k | Insider |
| Jonathan P. Northrup | 53.83% | 352,713 | $624.30k | Insider |
| Barton Pk LLC | 15.26% | 100,000 | $177.00k | Insider |
| John Sculley | 9.02% | 59,111 | $104.63k | Insider |
| Thomas 1. Wessel | 8.71% | 57,064 | $101.00k | Insider |
| David J. Arthur | 7.50% | 49,135 | $86.97k | Insider |
| Frederick Pierce Ii | 5.32% | 34,844 | $61.67k | Insider |
| Scott Jordan | 4.82% | 31,609 | $55.95k | Insider |
DCOY vs Biotech Stocks
Decoy Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.